首頁 > 市場調查報告書 > 製藥

藥物開發

市場調查報告書

商品編碼

1890966

Vyndaqel市場按適應症、療效、支付方、分銷管道、最終用戶、年齡層和地區分類

Vyndaqel Market, By Indication, By Strength, By Payer, By Distribution Channel, By End User, By Age group, By Geography

出版日期: 2025年11月20日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2025 年，Vyndaqel 市場價值將達到 83.7 億美元，到 2032 年將達到 198.1 億美元，2025 年至 2032 年的複合年成長率為 13.1%。

報告內容		報告詳情
基準年：	2024	2025年市場規模：	83.7億美元
歷史數據時期：	2020-2024	預測期：	2025-2032
預測期間（2025-2032年）：	13.10%	2032 年的預測值：	198.1億美元

全球Vyndaqel市場屬於專注於tafamidis的專科製藥領域。 tafamidis是一種突破性藥物，用於治療轉甲狀腺素類澱粉沉積症樣變性（ATTR）。 ATTR是一種罕見但進行性疾病，其特徵是轉甲狀腺素蛋白錯誤折疊和積累，會影響多個器官，尤其是心臟和周圍神經。 Vyndaqel由輝瑞公司在收購其原研發公司後主要負責市場推廣，現已成為治療遺傳性轉甲狀腺素類澱粉沉積症樣變性（伴神經病變的hATTR-PN）和轉甲狀腺素蛋白澱粉樣變性心肌病（ATTR-CM）的重要藥物。

該藥物作為一種轉甲狀腺素蛋白穩定劑，可防止四聚體轉甲狀腺素蛋白解離成單體，進而避免錯誤折疊形成澱粉樣蛋白沉積。隨著全球醫療體係日益重視罕見疾病治療和改善複雜疾病患者的預後，Vyndaqel市場正獲得顯著成長。診斷能力的提升、醫療專業人員對ATTR症狀認知的提高、各地區監管核准的擴大以及對罕見病精準醫療方法的日益關注，都顯著推動了該市場的成長，使其成為全球專科藥品市場的重要組成部分。

市場動態

全球Bindakel市場成長的主要促進因素包括：轉甲狀腺素類澱粉沉積症樣變性（ATTR）盛行率的上升、診斷調查方法的進步使得ATTR能夠早期、準確地檢測出來，以及醫療專業人員對該疾病多種表現形式（尤其是以往診斷不足的心臟表現）的認知不斷提高。全球人口老化也是市場成長的重要因素，因為ATTR-CM主要影響老年患者，而野生型轉甲狀腺素類澱粉沉積症也日益被認為是老年人心臟衰竭的病因之一。孤兒藥認定、快速核准核准和突破性治療方法認定等監管支持正在加速市場滲透，而由於適應症的擴大和區域性核准的增加，目標患者群體也在不斷擴大。此外，醫療保健領域在罕見疾病和專科藥物方面的支出不斷增加，加上已開發市場報銷政策的改善，正在提高患者獲得昂貴但能改變人生的治療的機會。

然而，市場存在諸多限制因素。治療費用每年可能超過20萬美元，對醫療系統造成沉重的經濟負擔，並限制了病患的就醫，尤其是在醫療預算有限的新興市場。此疾病的罕見性限制了患者數量，而其複雜多樣的症狀與其他疾病相似，使得診斷極具挑戰性，導致診斷和治療啟動的延遲。來自替代治療方法的競爭，例如新興的基因療法和其他正在研發中的緩解疾病療法，對市場佔有率構成潛在威脅。這種特殊藥物的生產複雜性和供應鏈挑戰可能會影響其供應和定價。然而，透過擴大診斷意識項目，可以識別出先前未確診的患者，尤其是在ATTR認知度仍然較低的醫療資源匱乏地區，這為患者帶來了巨大的機會。伴隨診斷和生物標記的開發有望簡化患者的識別和監測流程。此外，將適應症擴展到其他ATTR症狀和疾病早期階段，可顯著增加符合治療條件的患者數量。

本次調查的主要特點

本報告對全球 Vyndaqel 市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和複合年成長率百分比。
他還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
該研究根據以下參數對全球 Vindakeer 市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本研究涵蓋的主要企業包括輝瑞公司。
本報告的研究結果將使負責人和經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球Vyndaqel市場報告面向該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商和新參與企業。
相關人員可以透過分析全球 Bindoxel 市場所使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第11章競爭格局

Pfizer Inc.

第12章分析師建議

機會
一致的機會地圖

第13章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8971

Vyndaqel Market is estimated to be valued at USD 8.37 Bn in 2025 and is expected to reach USD 19.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 8.37 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	13.10%	2032 Value Projection:	USD 19.81 Bn

The global Vyndaqel market represents a specialized pharmaceutical segment focused on tafamidis, a breakthrough medication developed for treating transthyretin amyloidosis (ATTR), a rare but progressive disease characterized by the misfolding and accumulation of transthyretin proteins in various organs, particularly the heart and peripheral nerves. Vyndaqel, marketed primarily by Pfizer following their acquisition of the drug's original developer, has emerged as a critical therapeutic intervention for both hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and transthyretin amyloid cardiomyopathy (ATTR-CM).

The drug functions as a transthyretin stabilizer, preventing the dissociation of tetrameric transthyretin into monomers that subsequently misfold and form amyloid deposits. As healthcare systems worldwide increasingly recognize the importance of addressing rare diseases and improving patient outcomes for complex conditions, the Vyndaqel market has gained substantial momentum. The market's growth trajectory is significantly influenced by enhanced diagnostic capabilities, increased awareness among healthcare professionals about ATTR manifestations, expanding regulatory approvals across different regions, and the growing emphasis on precision medicine approaches for rare disease management, positioning this market as a crucial component of the global specialty pharmaceuticals landscape.

Market Dynamics

The global Vyndaqel market is primarily driven by the increasing prevalence of transthyretin amyloidosis, improved diagnostic methodologies that enable earlier and more accurate detection of ATTR, and growing awareness among healthcare professionals about the disease's varied presentations, particularly its cardiac manifestations which were historically underdiagnosed. The aging global population contributes significantly to market growth, as ATTR-CM predominantly affects elderly patients, with wild-type transthyretin amyloidosis becoming more recognized as a cause of heart failure in older adults. Regulatory support through orphan drug designations, fast-track approvals, and breakthrough therapy designations has accelerated market penetration, while expanded indications and geographical approvals continue to broaden the addressable patient population. Additionally, increased healthcare spending on rare diseases and specialty pharmaceuticals, coupled with improved reimbursement policies in developed markets, has enhanced patient access to this costly but life-changing therapy.

However, the market faces substantial restraints including the extremely high cost of treatment, which can exceed USD 200,000 annually, creating significant financial barriers for healthcare systems and limiting patient access, particularly in emerging markets with constrained healthcare budgets. The rarity of the disease results in a limited patient population, while diagnostic challenges persist due to the disease's complex and varied presentations that can mimic other conditions, leading to delayed diagnosis and treatment initiation. Competition from alternative treatment approaches, including emerging gene therapies and other disease-modifying treatments in development, poses potential market share threats. Manufacturing complexities and supply chain challenges for this specialized medication can impact availability and pricing. Nevertheless, significant opportunities exist through expanding diagnostic awareness programs that could identify previously undiagnosed patients, particularly in underserved geographical regions where ATTR recognition remains limited. The development of companion diagnostics and biomarkers could streamline patient identification and monitoring, while potential label expansions to additional ATTR manifestations or earlier disease stages could substantially increase the treatable patient population.

Key Features of the Study

This report provides in-depth analysis of the global Vyndaqel market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Vyndaqel market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key company covered as a part of this study include Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Vyndaqel market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Vyndaqel market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, wild-type)
- Hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, variant)
- Transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP)
Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 20 mg
- 61 mg
Payer Insights (Revenue, USD Bn, 2020 - 2032)
- Public
- Private
- Self-pay/Out-of-pocket
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital pharmacies
- Specialty/Online pharmacies
- Retail pharmacies
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Cardiac Amyloidosis Centers
- Ambulatory Surgical Centers
- Homecare Settings
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adults (>=18 yrs)
- Elderly (>=65 yrs)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Pfizer Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Vyndaqel Market, By Indication
- Global Vyndaqel Market, By Strength
- Global Vyndaqel Market, By Payer
- Global Vyndaqel Market, By Distribution Channel
- Global Vyndaqel Market, By End User
- Global Vyndaqel Market, By Age group
- Global Vyndaqel Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Vyndaqel Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, wild-type)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, variant)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Vyndaqel Market, By Strength, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
61 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Vyndaqel Market, By Payer, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Self-pay/Out-of-pocket
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Vyndaqel Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty/Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Vyndaqel Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiac Amyloidosis Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Vyndaqel Market, By Age group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adults (>=18 yrs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Elderly (>=65 yrs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Vyndaqel Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

12. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

13. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

Vyndaqel市場按適應症、療效、支付方、分銷管道、最終用戶、年齡層和地區分類

Vyndaqel Market, By Indication, By Strength, By Payer, By Distribution Channel, By End User, By Age group, By Geography

市場動態

目錄

第1章研究目標與前提條件

第2章市場範圍

第3章：市場動態、監理及趨勢分析

4. 2020-2032年全球Vyndaqel市場依適應症分類

5. 2020-2032年全球Vyndaqel市場依效力分類

6. 2020-2032年全球Vyndaqel市場按支付方分類

7. 2020-2032年全球Vyndaqel市場按分銷管道分類

8. 2020-2032年全球Vyndaqel市場（依最終用戶分類）

9. 2020-2032年全球Vyndaqel市場依年齡層別分類

第10章全球Vyndaqel市場（按地區分類），2020-2032年

第11章競爭格局

第12章分析師建議

第13章參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Vyndaqel Market, By Indication, 2020-2032, (USD Bn)

5. Global Vyndaqel Market, By Strength, 2020-2032, (USD Bn)

6. Global Vyndaqel Market, By Payer, 2020-2032, (USD Bn)

7. Global Vyndaqel Market, By Distribution Channel, 2020-2032, (USD Bn)

8. Global Vyndaqel Market, By End User, 2020-2032, (USD Bn)

9. Global Vyndaqel Market, By Age group, 2020-2032, (USD Bn)

10. Global Vyndaqel Market, By Region, 2020 - 2032, Value (USD Bn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

Vyndaqel市場按適應症、療效、支付方、分銷管道、最終用戶、年齡層和地區分類

Vyndaqel Market, By Indication, By Strength, By Payer, By Distribution Channel, By End User, By Age group, By Geography

市場動態

目錄

第1章 研究目標與前提條件

第2章 市場範圍

第3章：市場動態、監理及趨勢分析

4. 2020-2032年全球Vyndaqel市場依適應症分類

5. 2020-2032年全球Vyndaqel市場依效力分類

6. 2020-2032年全球Vyndaqel市場按支付方分類

7. 2020-2032年全球Vyndaqel市場按分銷管道分類

8. 2020-2032年全球Vyndaqel市場（依最終用戶分類）

9. 2020-2032年全球Vyndaqel市場依年齡層別分類

第10章 全球Vyndaqel市場（按地區分類），2020-2032年

第11章 競爭格局

第12章 分析師建議

第13章 參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Vyndaqel Market, By Indication, 2020-2032, (USD Bn)

5. Global Vyndaqel Market, By Strength, 2020-2032, (USD Bn)

6. Global Vyndaqel Market, By Payer, 2020-2032, (USD Bn)

7. Global Vyndaqel Market, By Distribution Channel, 2020-2032, (USD Bn)

8. Global Vyndaqel Market, By End User, 2020-2032, (USD Bn)

9. Global Vyndaqel Market, By Age group, 2020-2032, (USD Bn)

10. Global Vyndaqel Market, By Region, 2020 - 2032, Value (USD Bn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

第1章研究目標與前提條件

第2章市場範圍

第10章全球Vyndaqel市場（按地區分類），2020-2032年

第11章競爭格局

第12章分析師建議

第13章參考文獻與調查方法